This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roth, A. Articles by Elkayam, U. Search for Related Content PubMed PubMed Citation Articles by Roth, A. Articles by Elkayam, U. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Atrial Fibrillation Hazardous Substances DB DIGOXIN DILTIAZEM

Circulation, Vol 73, 316-324, Copyright © 1986 by American Heart Association

ARTICLES

Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation

A Roth, E Harrison, G Mitani, J Cohen, SH Rahimtoola and U Elkayam

We evaluated the efficacy and the safety of medium-(240 mn/day) and high-dose (360 mg/day) diltiazem alone and in combination with digoxin when used for control of heart rate in 12 patients with chronic atrial fibrillation. Medium-dose diltiazem was comparable to therapeutic dose of digoxin at rest (88 +/- 19 vs 86 +/- 12 beats/min) but superior during peak exercise (154 +/- 23 vs 170 +/- 20 beats/min; p less than .05). High-dose diltiazem resulted in better control of heart rate than digoxin both at rest (79 +/- 17 beats/min; p less than .05) and exercise (136 +/- 25 beats/min; p less than .05) but was associated with side effects in 75% of the patients. Combined therapy of digoxin and diltiazem enhanced the effect of digoxin alone and resulted in significantly better control of heart rate at rest (67 +/- beats/min with medium-dose and 65 +/- beats/min with high-dose diltiazem) and during peak exercise (132 +/- 32 and 121 +/- 24 beats/min, respectively). However, the difference in heart rate between these two doses was not significant. Reduction of heart rate combined with concomitant effect on blood pressure resulted in a significant fall in pressure-rate product at rest from 10,077 +/- 1708 mm Hg/min on digoxin alone to 7877 +/- 1818 mm Hg/min after the addition of medium-dose diltiazem (p less than .05) and during exercise form 25,670 +/- 3606 to 18,439 +/- 4115 mm Hg/min (p less than .05). Continued therapy with digoxin combined with diltiazem 240 mg/day for 21 +/- 8 days in nine patients showed persistent effect on heart rate and blood pressure without any toxic manifestations or change in serum digoxin (1.5 +/- 0.4 vs 1.3 +/- 0.4 ng/ml) or plasma diltiazem concentrations (204 +/- 72 vs 232 +/- 129 ng/ml). In conclusion, medium-dose diltiazem when combined with digoxin is an effective and safe regimen for the treatment of patients with chronic atrial fibrillation and enhances digoxin-mediated control of heart rate both at rest and during exercise.

This article has been cited by other articles:

				T Nikolaidou and K S Channer Chronic atrial fibrillation: a systematic review of medical heart rate control management Postgrad. Med. J., June 1, 2009; 85(1004): 303 - 312. [Abstract] [Full Text] [PDF]

				T. Nikolaidou and K. S Channer Rate control in permanent atrial fibrillation BMJ, November 24, 2007; 335(7629): 1057 - 1058. [Full Text] [PDF]

				B. Olshansky, L. E. Rosenfeld, A. L. Warner, A. J. Solomon, G. O'Neill, A. Sharma, E. Platia, G. K. Feld, T. Akiyama, M. A. Brodsky, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: Approaches to control rate in atrial fibrillation J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1201 - 1208. [Abstract] [Full Text] [PDF]

				C.J. Boos, J. Carlsson, and R.S. More Rate or rhythm control in persistent atrial fibrillation? QJM, December 1, 2003; 96(12): 881 - 892. [Abstract] [Full Text] [PDF]

				W. S. Aronow Management of the Older Person With Atrial Fibrillation J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2002; 57(6): M352 - 363. [Abstract] [Full Text]

				R. H. Falk Atrial Fibrillation N. Engl. J. Med., April 5, 2001; 344(14): 1067 - 1078. [Full Text] [PDF]

				N. Wattanasuwan, I. A. Khan, N. J. Mehta, P. Arora, N. Singh, B. C. Vasavada, and T. J. Sacchi Acute Ventricular Rate Control in Atrial Fibrillation : IV Combination of Diltiazem and Digoxin vs IV Diltiazem Alone Chest, February 1, 2001; 119(2): 502 - 506. [Abstract] [Full Text] [PDF]

				G. E. Kochiadakis, E. M. Kanoupakis, M. D. Kalebubas, N. E. Igoumenidis, K. E. Vardakis, H. E. Mavrakis, and P. E. Vardas Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study Europace, January 1, 2001; 3(1): 73 - 79. [Abstract] [PDF]

				R. Farshi, D. Kistner, J. S. M. Sarma, J. A. Longmate, and B. N. Singh Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens J. Am. Coll. Cardiol., February 1, 1999; 33(2): 304 - 310. [Abstract] [Full Text] [PDF]

				M. A. Brodsky, J. G. Chun, P. J. Podrid, S. Douban, B. J. Allen, and R. Cygan Regional Attitudes of Generalists, Specialists, and Subspecialists About Management of Atrial Fibrillation Arch Intern Med, December 9, 1996; 156(22): 2553 - 2562. [Abstract] [PDF]

				E. N. Prystowsky, D. W. Benson Jr, V. Fuster, R. G. Hart, G. N. Kay, R. J. Myerburg, G. V. Naccarelli, and D. G. Wyse Management of Patients With Atrial Fibrillation : A Statement for Healthcare Professionals From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association Circulation, March 15, 1996; 93(6): 1262 - 1277. [Full Text]

				A. Roth, E. Kaluski, S. Felner, K. Heller, and S. Laniado Clonidine for Patients with Rapid Atrial Fibrillation Ann Intern Med, March 1, 1992; 116(5): 388 - 390. [Abstract] [PDF]

				R. H. Falk and J. I. Leavitt Digoxin for Atrial Fibrillation: A Drug Whose Time Has Gone? Ann Intern Med, April 1, 1991; 114(7): 573 - 575. [Abstract] [PDF]